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Abstract 
 
Synthetic sling surgery is the procedure of choice for surgical correction of 
stress urinary incontinence (SUI) in females. However, complications do 
occur, and may require surgical intervention to treat them in some instances. 
In a retrospective study we identified and analyzed those complications to 
determine their incidence and associated predictive factors. A total of 59,887 
women who had synthetic sling procedure were included. Incidence of 
surgically treated complications was 2.2 % ((95% CI 2.07- 2.30) and at 10 
years follow up cumulative incidence rate was 3.3% (95% CI 3.0- 3.5). 
There was no significant difference in complication rate between urologists 
versus gynecologists. A significant reduction in complications was noted 
with high surgical volume providers (HR 0.73, 95% CI 0.65-0.83). Patient’ 
factors like age and simultaneous surgeries had significant effect. Results 
support the Food and Drug Administration recommendation about use of 
synthetic meshes and slings in vaginal surgery.  
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Synthetic /mesh slings, Sling Revision, Stress Urinary Incontinence, 
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1    Introduction 
  
Stress urinary incontinence (SUI) is considered a common condition in 
women with considerable socioeconomic impacts. Depending on its 
severity, therapeutic options differ. Surgical intervention with urethral slings 
is currently the procedure of choice for SUI correction in females (1). 
However, complications are well documented and necessitate removal or 
release some-times. In this thesis, we will demonstrate the results of a 
retrospective study in which the incidence of SUI surgery in women was 
measured and rate of surgically treated post sling complications were 
documented. Factors that might influence complications were also identified 
and discussed in view of statistics and literatures. 
 
 
1.1 Stress Urinary Incontinence (SUI) in females 
 
Stress urinary incontinence (SUI) in females is a common condition. It’s 
considered to be symptom, sign and clinical disease. It is defined as 
“symptomatic complaint of involuntary leakage of urine on effort or 
exertion, and it can be noted in urodynamic study (UDS) as involuntary 
leakage of urine during increases in abdominal pressure in the absence of a 
detrusor contraction—so-called urodynamic stress incontinence” (2). 
Literature shows variable percentages of women affected by SUI, likely due 
to inconsistencies in definitions used by different investigators, which give a 
percentage between 15- 80% of women suffering from SUI (2).  
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1.1.1 Pathophysiology of SUI 
Pathophysiology of SUI in females was studied and reviewed as early as 19th 
century (Sinclair AJ). At that time anatomic theories were postulated to 
understand and diagnose incontinence. Textbooks of that era reflected such 
opinions, and in an old gynecology book the author hypothesized that “the 
cause… is usually a prolapse of the anterior vaginal wall” and “incontinence 
is also of common occurrence” (3). 
With advancement in technology and diagnostic tools in the early 20th 
century, a deeper understanding of pathophysiology of SUI was achieved 
and different theories evolved. The pressure transmission theory and 
sphincteric dysfunction theory were proposed and examined with repeated 
modifications over time (4). Currently, female SUI is thought to be the result 
of the combination of urethral hypermobility and intrinsic sphincteric 
dysfunction (ISD) (2). When intra-abdominal pressure increases due to 
cough or any other strenuous activity, the posterior wall of the urethra moves 
away from the anterior urethral wall. This causes opening of bladder neck 
due to urethral hypermobility, and leads to a loss of urine. ISD however, 
arises from defects within the urethra proper itself, so that the urethral 
sphincter is unable to close properly and generate enough resting urethral 
closing pressure to hold urine in the bladder (2). 
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1.1.2 Classification of SUI 
Classification of SUI was proposed and modified by several investigators 
since 1920s (4). Blaivas and Olsson modified a classification system 
proposed by McGuire and colleagues (Table 1.1). This system was founded 
based on the position of the vesical neck in relation to symphysis pubis and 
it’s descent during increase intra-abdominal pressure (diagnosed while 
imaging with fluoroscopy). It also monitors the integrity of the intrinsic 
sphincter mechanism (4).  
Table 1.1 Classification of Urinary Incontinence by Blaivas and Olsson 
Classification Finding at Rest Finding during Cough 
Type 0 Flat bladder above 
symphysis pubis 
Rotational descent of urethra and 
bladder base; no urine leakage 
Type I Flat bladder base above 
inferior margin of 
symphysis pubis 
Bladder base descends less than 2 cm 
in relation to pubis; bladder neck and 
urethra both open with leakage 
Type IIA Flat bladder base above 
inferior margin of 
symphysis pubis 
More then 2 cm descent of bladder 
and urethra below pubis; urethra open 
with leakage 
Type IIB Flat bladder base at or 
below inferior margin of 
symphysis pubis 
More descent and rotation of bladder 
and urethra below pubis; urethra open 
widely with leakage 
Type III Bladder base rests above 
symphysis pubis; bladder 
neck and urethra are open 
Bladder base above or below 
symphysis pubis; both bladder neck 
and urethra are open 
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1.1.3 Management of SUI 
SUI has a significant life impact on patient in multiple aspects, and 
depending on the degree of incontinence and patient’s coping strategies this 
impact can range between mild anxiety and fear of public activities to a full 
blown condition of depression and social isolation. Several areas of life can 
be affected such as social activities, physical performance and sports, sexual 
relationships, and even sleep may be affected (3). It is very important to 
consider and evaluate SUI impact on patient’s life and follow it through out 
the treatment period.  
Depending on severity of the condition, together with other patient factors, 
therapeutic options for SUI in women widely differ. Non-surgical 
intervention is well-established and recommended as first line therapy for 
urinary incontinence (UI) in form of behavioral (e.g. pelvic floor muscle 
rehabilitation) and pharmacological therapy (e.g. tricyclic antidepressant 
agent) (2). Such treatment modalities usually need high level of motivation 
and long-term commitment by patients. Surgical intervention aims to 
improve support to urethrovesical junction and strengthen all mechanisms 
contributing to continence. Different surgical methods have been described 
with variable success rates (2). Usually it’s the surgeon’ preference and 
training that play the most important role in choosing type of anti 
incontinence surgery. Other factors also contribute to the decision like the 
anatomical nature of incontinence and general health condition of the 
patients. 
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1.2 Sling Surgery for SUI 
Urethral sling surgery is currently the procedure of choice for SUI with a 
variety of techniques and materials (2). It’s routinely performed vaginally or 
abdominally (open or laparoscopic). In 2004, access through obturator 
foramen was described. Different materials have been consumed for sling 
fashioning, like autologous, allograft, xenograft, and synthetic materials. 
 
1.2.1 History of Sling Surgery 
Von Giordano first introduced the concept of sling surgery in 1907 as he 
used gracilis muscle graft wrapped around urethra (2). Frangenheim used 
rectus abdominis muscle and fascia in 1914, then, Millin adapted it for use in 
recurrent SUI (2). In 1933, Price used fascia lata to treat urinary 
incontinence in women with sacral agenesis, and he fixed it to the rectus 
muscle (5). Aldridge in 1940s described the use of paired strips of rectus 
fascia to form a sling and sutured them below the urethra (2). In 1970s, 
McGuire used the pubovaginal sling (PVS). He placed it at the bladder neck 
to correct urethral hypermobility and decrease the pressure transmission due 
to intra-abdominal pressure changes (2). First, it was used in patients who 
failed previous retropubic suspension procedures, and had a cure rate of 
91%, which was why this procedure was reintroduced. Zaccharin in the 
1960s and DeLancey in the 1990s hypothesized competing theories in which 
the role of pubourethral ligaments in maintaining urinary control was 
emphasized (2). They also stressed the role of midurethral mechanism in 
maintaining urinary continence under stress conditions (2). In 1990s, 
 6 
Ulmsten described his midurethra theory, (previously known as integral 
theory), and it’s first formulation was published in 1990 (6): 
 “For different reasons, stress and urge derive mainly from laxity in the 
vagina or it’s supporting ligaments, a result of altered collagen/elastin”  
Ulmsten postulated that injury due to different reasons such as surgery, 
aging, and parturition lead to weakening of the pubourethral ligaments. This 
affects the midurethral and anterior urethral wall support, which results in 
urinary incontinence (2). Radiological investigations later on provided a 
higher level of proof, and ultrasound technique brought a deeper 
understanding of vesicourethral dynamics after placement of sling (2) (6), 
which even further improved the understanding of continence mechanism in 
view of midurethra theory. Using those theories, the concept of mid urethral 
sling was developed, and since then, different approaches evolved with 
different materials and different suspension/fixation techniques. 
 
1.2.2 Different Materials of Slings 
Slings have been fashioned from various substances. A broad classification 
categorizes those substances to: autologous, allograft, xenograft, or synthetic 
materials. Ideally, sling material should be easily integrated into the host 
with the least tissue reaction, promote organized fibrosis, and be compatible 
with tissues (2). 
Autologous slings were used in the late twenty-century. The most common 
material used currently is rectus fascia. A pronounced benefit of this type of 
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material is the lack of tissue reaction, which decrease risk of erosion 
significantly  (7). Studies suggest that when autologous fascia is implanted 
there is a minimal to moderate inflammatory response, a moderate degree of 
collagen production, and a considerable degree of graft remodeling over the 
long term with reported rate of cure over 90% (7). However, such surgical 
approach increases operative time, prolongs recovery period post operatively 
with relative increase in pain, and limits the supply of the sling material. 
Also, the fact that another wound site is created for harvesting the sling adds 
to autologous disadvantages. Yet, they are considered to be the most 
successful biological material used in contemporary SUI surgery (7). 
When allograft materials are used as SUI-slings, operative time decreases 
and the harvest wound is eliminated. Currently, allograft slings are derived 
from cadaveric fascia late or acellular human dermis. Before it’ s implant, 
allografts undergo a long process of cleaning, sterilization and occasionally 
radiation to eradicate infective organisms and eliminate genetic materials 
before it is implanted (2) (7). Several studies evaluated changes in the 
mechanical properties of allografts after implantation, and results were 
mixed (7), however, histologic analysis revealed cadaveric dermis to have 
minimal host fibroblast infiltration and little neovascularity with marked 
thinning and degradation of the graft (2) (7). This may affect their long-term 
success rate. Another concern is low potential of disease transfer due to the 
low risk of erosion. There have been no cases reported yet of a disease 
transfer after allograft sling implantation, however, cases of HIV and 
Creutzfeldt-Jakob disease (CJD) transmission have been reported after 
transplantation of other cadaveric tissues (2). Although the risk of disease 
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transmission is low, human DNA has been detected in various allograft 
materials with an unknown clinical significance (2). 
Xenograft has been used since the 1980s with less frequent use in recent 
years. Types available for use are porcine dermis or small intestinal 
submucosa (SIS) and bovine pericardium. As an allograft, xenograft tissue 
undergoes processing techniques in order to make it safer and more pliable 
(2). Sometimes, porcine dermis undergoes further crosslinking to make it 
more resistant to enzymatic digestion, and when laboratory studies evaluated 
mechanical properties and host response to xenograft different results were 
retrieved based on the material being cross-linked or not (7). Xenograft has 
significant lower tensile strength after implantation, and it has little or no 
inflammatory reaction, which results in subsequent limited collagen 
remodeling and graft degradation (2) (7). In a randomized multicenter 
clinical trial conducted to compare porcine xenograft sling, short autologous 
fascial sling and the synthetic tension free vaginal tape (TVT) in stress 
incontinence surgery, the re-operation rate for delayed failure of xenograft 
slings was significantly worse than both the TVT or fascia (8).  
Synthetic slings were introduced for the first time in 1953 and were made of 
Nylon (2). Since then, range of synthetic materials have been used in SUI 
surgery with Gynecare TVT (Ethicon Women’s Health & Urology, 
Somerville, NJ) being the first implantable mesh sling device, and it was 
composed of a polypropylene material (9). Synthetic slings have obvious 
advantages over all other types of slings: more uniform and consistent, more 
durable, unlimited supply of graft material in various sizes and shapes, and 
elimination of harvest sites, which consequently positively influences 
operative time and post operative pain and recovery. Also, the potential low 
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risk of disease transfer with biological materials is absent in the case of 
mesh. Regarding their mechanical properties, synthetic slings are greatly 
affected by the physical characteristics of the mesh, such as filament count, 
porosity, and polymer molecular weight (7).  
In general, mesh stimulates a pronounced degree of inflammation, leading to 
massive cell infiltration and ultimate collagen production (2) (7). There is no 
degradation of the graft, and the mesh is usually completely infiltrated by the 
host tissue.  
Significant differences exist between surgical meshes available today, such 
as type of material, amount of yarn, and amount of construction (10). 
Generally, they are classified into four classes depending on their pores size 
(Table 1.2). 
Table 1.2 Amid Classification of Surgical Synthetic Materials 
 
 This classification by Amid (1997) was used originally for synthetic 
materials in hernia surgery, and it’s applied to urology as well (2). Type I 
mesh is totally macroporous, which facilitates its infiltration with 
macrophages, blood vessels, and collagen fibers. Type II includes materials 
Type Description Brands 
I Pores > 75 µm  
Macroporous 
Atrium, Trelex, Marlex, Prolene, 
Polypropylene  
II Pores < 10 µm 
Microporous 
GORE-TEX, Surgical Membrane, Dualmesh 
III Macroporous with 
multifilamentous or 
microporous components 
Teflon, Mersilene, Surgipro, MicroMesh 
IV Submicronic pore size Silastic, Cellcard 
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with pore size less than 10 µm. Type III includes prosthesis that is 
macroporous with multifilamentous or microporous components. Lastly, 
type IV includes materials with submicronic pore size (2). The most 
commonly used synthetic material for SUI slings is propylene mesh, which 
is composed of loosely woven strands with pore size greater than 80 µm. 
This allows movement of inflammatory cells during initial response and 
later on better host tissue ingrowth (2). Different types of synthetic slings 
available commercially are explained in Table 1.3. 
Table 1.3 Synthetic Sling Different Materials 
Trade Name Composition Details 
Mersilene Polyethylene terephthalate Multifilament fibers, very porous, 
firmly embedded in native tissues 
Teflon Polytetrafluroethylene 
(PTEF) 
Multifilament 
GOR-TEX Expanded PTFE Very flexible 
Silastic Silicone plus woven 
polyethylene terephthalate 
Minimal tissue reaction, easy removal 
or revision if necessary 
 
ProteGen Synthetic mesh with 
collagen matrix 
Removed from market due to high rate 
of vaginal extrusion 
Marlex, Prolene Polypropylene Monofilament with open-weave 
pattern 
 In spite all advantages of synthetic slings; serious disadvantages with 
variable occurrence rate do exist. Depending on physical properties of the 
mesh and the host inflammatory response, histological changes to the 
surrounding tissues occur, and might cause genitourinary erosion, vaginal 
extrusion or infection (2). Those disadvantages were noted to be more 
pronounced if synthetic sling was used as PVS, so it’s not used for this 
surgery (2), and more commonly used in a midurethral positioning.  
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1.2.3 Surgical Approaches of Sling Surgery 
 
Different surgical approaches have been described for synthetic sling. 
Choosing the specific approach is highly influenced by patient factors and 
criteria of her incontinence. One approach that is less commonly used 
currently is abdominal approach (5). It’s used mainly when restrictions to 
lithotomy position cannot be overcome, or in the rare event of concurrent 
sling placement at the time of abdominal surgery. With this approach, the 
retropubic space is opened, with a tunnel created under bladder neck and 
proximal urethra, then, a sling is passed in that tunnel without vaginal 
incision and brought up to either Cooper’s ligament or rectus fascia (5). The 
drawback of the abdominal approach is the risk of placing the sling too 
distally, which increases the risk of obstruction. Also, there might be a need 
to open the bladder to help in the dissection at the bladder neck level (5). 
 
Abdomino-vaginal approach is more common than abdominal only approach 
(5). It has the advantage of simultaneous vaginal and abdominal repair when 
required. With this technique, accurate placement of the sling under bladder 
neck is achieved by dissecting both retropubic space and vaginal wall, with 
less dissection required retropubicly (5). Its benefits are markedly apparent 
in cases of recurrent SUI in which good access to both anterior vaginal wall 
and retropubic space is needed (5). 
 
Vaginal approach is the commonest approach used for sling placement in 
SUI surgery. Both PVS and midurethral sling (MUS) are placed through this 
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access with help of special needles or introducers. Patient is placed in 
lithotomy position, and a longitudinal incision in the anterior vaginal wall is 
carried out at the level of bladder neck or midurethra. Depending on the SUI 
surgical kit, technique of placing and positioning sling differs. Initially, TVT 
was placed via a through vaginal incision through the retropubic space, 
(bottom-to-top approach). Later on, retropubic top-to-bottom approach has 
been introduced as the suprapubic arc system (SPARC, American Medical 
Systems, Inc., Minnetonka, MN, USA). (See Figure 1.1) 
Then, a significant modification to the MUS insertion technique was 
introduced; the transobturator MUS (TMUS) was designed to avoid the 
blind passage of the needle through the retroperitoneal space (11). In this 
approach, needle traverses through obturator foramen for fixing the tape. 
First, it was inserted in an outside-in technique only, and then a second 
technique with an inside-out placement of the sling was described.   
 
 
Figure 1.1 Vaginal approach in midurethral sling (MUS) placement via retropubic, 
bottom-to-top route. 
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Figure 1.2 Vaginal approach of midurethral sling (MUS) Placement via 
transobturator route. 
 
 
The vaginal approach continued to have modifications as new sling kits were 
developed and marketed. A single-incision sling was developed as a less 
invasive procedure with comparable subjective and objective cure rates in 
short term follow up. It may have a quicker recovery period and may have a 
lower risk of some complications; however, adverse effects like mesh 
erosion and urinary retention are not absent (11). Table 1.4 displays different 
surgical kits of slings available in the market with their surgical approaches 
and techniques. 
 
Table 1.4 Commercial Synthetic Slings Kits 
Name Manufacturer Technique/Approach 
TVT Ethicon RMUS bottom to top 
TVT-O Ethicon TMUS inside to out 
TVT-Secure Ethicon Single incision 
SPARC AMS RMUS top to bottom 
Monarc AMS TMUS outside to in 
MiniArc AMS Single incision 
 14 
Name Manufacturer Technique/Approach 
Advantage Boston Scientific RMUS bottom to top 
Lynx Boston Scientific RMUS top to bottom 
ObTryx Boston Scientific TMUS outside to in 
Solyx Boston Scientific Single incision 
Aris Coloplast TMUS outside to in 
Ajust Bard Single incision 
(Adjustable sling) 
 
 
1.3 Complications of Sling Surgery 
 
   As previously explained, there are different approaches and techniques of 
anti incontinence surgery using slings. Complications vary according to 
material and approaches.  
As our study was to evaluate synthetic sling complications and potential risk 
factors, we will focus on complications of synthetic slings in subsequent 
discussion.  
 
 
1.3.1 Classification of Synthetic Sling Complications 
 
Complications in general can be classified to different groups and divisions 
depending on time of seeking medical advice, severity of complications, or 
site of occurrence of complications. Synthetic sling complications are 
significantly related to surgical approaches and/ or technique used in the 
surgery. Before we elaborate on such classification, we should display the 
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classification of the complications of meshes and tapes proposed by the 
International Urogynecological Association (IUGA) and the International 
Continence Society (ICS) Joint meeting in 2010. This classification aimed to 
be a basis for a registry of such complications and an aid to clinical practice 
and research (12). It categorizes the complications in relation to the insertion 
of prostheses and grafts in pelvic floor surgery in females, and it is based on 
category (C), time (T) and site (S) classes and divisions, in hopes of 
encompassing all possible scenarios for describing insertion complications 
and healing abnormalities of those surgeries. It uses numerals and letters 
(see Tables 1.5-6). In categories (C), seven divisions were composed to 
describe vaginal, urinary tract, rectal or bowel, skin and/or musculoskeletal 
and patients’ specific complications. Each category is subdivided into 
further classes depending on category’ criteria and description. The second 
component of the classification is time (T), which describes the time of 
clinical diagnosis of that complication. It has four divisions; the earliest time 
might involve insertion issues of the mesh/tape, whilst later divisions are 
usually related to healing abnormality issues. The third component of this 
classification describes the site (S) of the complication. As one might expect, 
possible sites of tape complications are vaginal, trocar passage, 
musculoskeletal, and intra-abdominal. One division is entitled as systemic 
complications with no specific site.  
 
This classification was hoped to be useful for all parties involved in female 
pelvic floor surgeries like anti incontinence procedures and prolapse repair, 
including surgeons, physicians, nurses, and industry, so all of them will be 
referring to the same clinical issue in consistency. Examples of how this 
classification can be applied clinically are illustrated in Table 1.7. 
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IUGA/ICS classification has been evaluated and applied in study conducted 
by Petri et al. and results were published in 2012 (13). They studied 376 
women with complications of synthetic slings, which were managed 
surgically, and after analysis of data, they found that new IUGA-ICS 
classification could be applied to most of the types of complications. 
However, de novo development of overactive bladder (OAB) was not 
included. The study recommended application of this classification in 
clinical practice with minor modifications such as inclusion of OAB as a 
complication of the synthetic sling surgeries. This recommendation was 
based on their review of complication cases in which they found that 
development of de novo OAB symptoms was the commonest complication 
encountered (13). However, still this classification is not widely adopted by 
neither clinical studies nor surgeons involved in management of SUI and/ or 
pelvic organ prolapse (POP) repair. 
 
Table 1.5 International Urogynecological Association (IUGA)/International 
Continence Society (ICS) Joint Classification of Complications Related Directly to 
the Insertion of Meshes in Female Pelvic Floor Surgery: CATEGORY (C) 
 
 General 
Description 
A  
(Asymptomatic) 
B  
(Symptomatic) 
C 
(Infection) 
D 
(Abscess) 
1 Vaginal 
 No epithelial 
separation 
1A  
Abnormal graft 
finding on 
examination 
1B Symptomatic 
(e.g. pain, 
dyspareunia) 
1C 
Infection 
1D 
Abscess 
2 Vaginal 
Exposure >= 
1cm 
2A Asymptomatic 2B Symptomatic 2C 
 Infection 
2D 
Abscess 
3 Vaginal 
Exposure < 2cm 
3A Asymptomatic 3B Symptomatic 3C  
Infection 
3D 
Abscess 
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 General 
Description 
A  
(Asymptomatic) 
B  
(Symptomatic) 
C 
(Infection) 
D 
(Abscess) 
4 Urinary Tract 
Perforation, 
fistula, calculus 
4A  
Small 
intraoperative 
defect (bladder 
perforation) 
4B  
Other LUT 
Complication/ 
Retention 
4C Ureteric or upper 
urinary tract complication 
5 Rectal or 
Bowel 
Perforation, 
fistula 
5A  
Small 
intraoperative 
defect 
5B  
Rectal injury or 
compromise 
5C  
Small or 
large bowel 
injury or 
compromise 
5D  
Abscess 
6 Skin and/ or 
Musculoskelet
al  
discharge, pain, 
sinus tract 
formation 
6A Asymptomatic, 
abnormal finding 
on examination 
6B Symptomatic 
e.g. discharge, 
pain or lump 
6C  
Infection e.g. 
sinus tract 
formation 
6D 
Abscess 
7 Patient 
Compromise 
like hematoma 
7A  
Bleeding 
complication 
7B 
Major degree of 
resuscitation or 
intensive care 
7C 
Mortality 
 
 
 
Table 1.6 An International Urogynecological Association (IUGA)/International 
Continence Society (ICS) Joint Classification of Complications Related Directly to 
the Insertion of Meshes in Female Pelvic Floor Surgery: TIME (T) and SITE (S) 
 
TIME 
TI 
Intraoperative -
48 hours 
T2  
48 hours- 2 
months 
T3 
2 months- 
12 months 
T4 
Over 12 month 
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SITE 
S1 Vaginal; area 
of suture line 
S2 Vaginal; 
away from area 
of suture line 
S3  
Trocar 
passage  
Except S5 
S4 
Other skin or 
musculoskeletal 
site 
S5  
Intra-
abdominal 
 
 
 
Table 1.7 Examples of Complications Related to Mesh-based Surgery in Female 
Using the International Urogynecological Association (IUGA)/ International 
Continence Society (ICS) Joint Classification System 
Patient ID Clinical Description of 
Complication 
Code Code 
100 Retropubic hematoma following a 
tape procedure (first 24 hours) 
7A/T1/S3  
101 Persistent thigh pain six weeks after 
an obturator tape 
6B/T2/S4  
102 Bowel obstruction and 2 cm vaginal 
vault exposure with bleeding six 
months after a mesh sacrocolpopexy 
5C/T3/S5 3B/T3/S1 
 
 
 
1.3.2 Complications of Synthetic Slings Placed via 
Transobturator Approach 
 
The anatomic differences between the inside-out and outside-in approaches 
of transobturator tape (TOT) insertion have been compared, especially in 
terms of adverse outcomes. One method of studying such differences in 
anatomy was through cadaveric dissection of the pelvis after performing 
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sling surgery. When studying the inside-out technique of TOT insertion of 
the sling, the sling was found outside the pelvic space and did not penetrate 
the levator ani muscular group (2) (14). Risk of perforating bladder has been 
identified in those studies (2). Such injury is usually easily identified 
intraoperative if cystoscopy is carried out after passage of needle and tape. 
 
Vaginal erosion and extrusion risk appears to be significantly related to 
mechanical properties of the mesh utilized. An incidence of up to 15% of 
vaginal extrusion and erosion had been reported with old meshes, and 
obturator and ischiorectal abscesses, sinus formation, and voiding difficulty 
were all noted (2). Newer polypropylene slings have lower incidence of 
erosion and extrusion.  
 
Infectious complications also have been reported with TOT, such as 
abscesses, adductor myositis, and cellulitis (2). Cases of infected obturator 
hematoma requiring exploration and drainage have been also reported. As 
with vaginal erosion, risk of infectious complications decreased with the 
new slings. Urinary tract infection (UTI) has been reported to occur post 
TOT procedure in a rate between 7.4% and 13% (14), and it was under 
reported as postoperative complications, perhaps due to an improper 
definition and under reporting of UTI as a complication (14). It is usually 
managed with antibiotics with the same guidance and rules that govern the 
use of antibiotic for UTIsin other clinical scenarios. 
 
Postoperative voiding dysfunction has an incidence between 2.1% and 6.7% 
after TOT techniques (2). Urinary obstructive symptoms rate varies between 
1.5% and 15.6% of cases (2). They are usually temporary and managed with 
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short-term intermittent catheterization. Rarely, obstruction lasts longer than 
expected, and patients improve when the sling is incised or removed with a 
second operation (2).  
 
Postoperative leg pain is a unique complication to TOT procedures, reported 
in up to 15.9% of patients (2) (14). It’s usually transient, responds to non-
steroidal anti-inflammatory medications, and improves shortly after surgery. 
It’s likely due to subclinical hematoma or a transient neuropathic 
phenomenon (2). Pain can be felt down the leg or in the groin area. Cases 
that do not respond to conservative therapy should prompt investigation to 
role out tape erosion. Therapy with corticosteroids and local anesthetic 
agents might be required in some cases (2). Sling resection or urethrolysis 
sometime is needed. 
 
 
1.3.3 Complications of Synthetic Slings Placed via Retropubic 
Approaches 
 
 Vaginal erosion or exposure of sling into vagina is a complication following 
TVT procedure, similar to TOT slings (2). It’s manifested clinically by 
vaginal discharge, sexual discomfort or dyspareunia, non-specific lower 
urinary tract symptoms, and pelvic pain. However, up to one third of patients 
with vaginal erosion may be asymptomatic (14). Cases usually present 
within the first few weeks to few months of the procedure, and continence is 
usually maintained. Factors such as biomechanical properties of the mesh 
used, tissue healing and infection, thin, atrophic vaginal wall (as in post-
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menopausal status), and incorrect surgical technique all were addressed as 
influencing factors to vaginal erosion (14). Cases are managed on individual 
basis, and conservative management, surgical removal of the exposed mesh, 
and even more aggressive surgical intervention has been reported to be 
effective in managing mesh erosion or exposure (2) (14). 
 
Urethral erosion is a complication that can be associated with severe 
morbidity (14) (15). It’s rare after retropubic approaches of sling placement 
surgery, with an incidence of less than 0.3% (2) (14). Possible risk factors 
include compromised blood supply to the urethra (such as post radiation 
cases), excessive sling tension or twisting of the tape, and iatrogenic urethral 
injury intraoperative. Also, surgical technique may increase the risk of 
urethral erosion, as carrying out dissection too close to the urethra can cause 
urethral devascularization (2). Patients with urethral erosion present in most 
instances with voiding dysfunction symptoms like urgency and urge 
incontinence, urinary obstruction and/ or retention, and recurrent UTI. Also, 
persistent urinary incontinence is a potential symptom of erosion of the tape 
into the urethra (2). Intraoperative cystoscopy is highly recommended to 
identify iatrogenic injury to the urethra. It makes a significant difference in 
the patient outcome if an injury is addressed at the time of the procedure. 
There is no role for conservative management for urethral erosion, and cases 
that present later have to be treated with an endoscopic procedure or 
transvaginal urethrotomy and excision of the exposed tape (2). In cases with 
more urethral lumen or surface compromise, graft may have to be 
considered for repair. 
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Bladder perforation while passing the needle to place the sling in the vaginal 
wound has been reported with retropubic approach. Rates range between 
0.7% and 24%, and it’s mostly related to surgeon experience, as incidence 
was noted to decrease when experience with the procedure increased (14). 
As with urethral injury, bladder perforation can be identified and corrected 
intraoperatively if cystoscopy is performed. The trocar is repositioned and 
the sling is placed in the appropriate place, and an indwelling catheter is left 
for a few days post operative  (2). If it’s not addressed intraoperative, the 
patients may presents with irritative bladder symptoms such as urgency and 
frequency. Some cases may present with fistulas with need for more 
aggressive intervention (14). 
 
Intravesical tape erosion may be a distressing later symptom of bladder 
perforation if it was missed intraoperative. It is less common to have true 
erosion through the seromuscular layer of bladder (2). Typical symptoms 
might be lower abdominal pain, intermittent gross hematuria, recurrent UTI, 
frequency, urgency, and urinary incontinence. As with urethral erosion, ther 
is no role for conservative management in cases with intravesical sling 
erosion, and removal of a portion of tape with reconstruction of the urinary 
tract is the standard therapeutic approach (2). Patients usually maintain their 
continence if only the intravesical portion of the sling is removed. 
 
Voiding dysfunction is a well-documented complication after all sling 
surgeries (2) (16). It usually presents as varying degrees of urinary 
obstruction (2) (13) (14).  Reported incidence varies in different studies with 
rate between 1.9% and 19.7% (2) (14), and it seems that rate increases with 
prolonged follow up period (13). UDS has been used in multiple studies to 
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address parameters like urine flow, filling time, voiding time, and maximum 
voiding pressure, and compare those parameters before and after sling 
surgeries, thus, anticipate cases with possible post sling surgery voiding 
dysfunction. However, no enough evidences correlate UDS parameters with 
surgical outcome (2). Yet, it’s vital to identify factors that might negatively 
affect outcome and predispose to post operative urinary retention, like age, 
parity, and peak flow rate on UDS (16). Also, it was found that patients who 
have lower detrusor voiding pressure are more likely to have urinary 
retention postoperatively (16). Another factor that may increase the risk of 
voiding dysfunction after sling surgery is concomitant prolapse surgery (16). 
Finally, local tissue criteria like abnormal positioning of the sling at bladder 
neck level, scarring of the bladder neck, and presence of paravaginal defects 
have been noted in patients with urinary obstruction (13). Hypothesized 
mechanisms for urethral obstruction after sling surgery included 
hyperelevation of bladder neck and/ or an exaggerated kink in the urethra 
(16). Clinical picture includes different presentations; patient may complain 
of difficulty in initiation urine stream, straining while voiding, incomplete 
emptying or total urinary retention (2). A thorough history and physical 
examination are vital in the initial evaluation and before any surgical 
intervention is carried out. Cystoscopy helps in the diagnosis mainly through 
exclusion of other causes of urinary obstruction. First line of management 
includes temporarily indwelling catheter use, intermittent catheterization, or 
timed and double voiding (2) (14). If symptoms persist, surgical intervention 
is advised. It’s recommended to wait at least four weeks before surgical 
intervention is considered (2) (13) (14). Release of sling with minimal 
vaginal dissection is usually sufficient with maintained continence through 
the support of urethra from the remaining portions of the sling (2).  
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Other complications of sling surgery have been reported in minor 
percentages. Wound–related complications like infection, abscesses and UTI 
have been addressed. Serious complications like vascular injury and 
hemorrhage into pelvis have been also reported, and at least one case leading 
to mortality (2) (14). Postoperative dyspareunia has been reported in up to 
15% of patients who underwent sling surgery (2) (14). It was attributed to 
the physical properties of the sling that cause shrinkage and/ or migration. 
 
Review of the safety database of U.S Food and Drug Administration for 
complications reported to that agency is listed in Table 1.8. 
 
Table 1.8 Summary of All significant Complications Reported to the U.S Food and 
Drug Administration with Midurethral Sling (1998-2009) 
 
 
 
 
 
 
 
 
 
 
 
Complication  No. Of cases reported 
Bladder erosion 50 
Urethral erosion 51 
Vaginal erosion 239 
Bowel perforation 48 
Major vascular 26 
Blood loss > 200ml 36 
Plastic sheath malfunction 51 
Leg pain 44 
Needle broken from mesh 154 
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2     Literature Review  
 
 
    Complications of synthetic sling surgery can be related to patient’s 
factors, provider’ factors, surgical techniques, and the physical properties of 
sling itself. In the literature, complications were mainly described in relation 
to their time of diagnosis in postoperative follow up, or in relation to 
surgical approaches commenced in the surgery. As described previously, a 
recent classification system was standardized by IUGA and the ICS joint 
committee to describe and diagnose complications related to meshes, tapes, 
or implants surgery in female, however, it is not yet widely used in 
evaluation of those complications either in clinical practice or in literature.  
 
 
2.1 Food and Drug Administration (FDA) Warning about the 
Use of Surgical Mesh for SUI 
 
  After the approval of synthetic sling use in United States (USA) in 1998 by 
the Food and Drug Administration (FDA), urologists and gynecologists all 
over the world started performing mid-urethral sling surgeries. In 2011, over 
3 million mid-urethral slings had been sold worldwide (17). The procedure 
is considered safe, however, in October 2008, FDA issued a public health 
notification (and updated it on July 2011) about slings and meshes used in 
gynecological surgery (18) (19). The notification was issued after the agency 
received more than 1,000 reports of complications associated with the use of 
meshes for both pelvic organs prolapse (POP) repair and SUI correction. 
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Vaginal erosion, pain, infection, and recurrence of prolapse and/or 
incontinence were among those rare complications (18). FDA did not advise 
cessation of surgical meshes usage; it did recommend “specialized training 
for mesh placement technique” and thorough counseling with patients about 
properties of mesh, and “that complications associated with the implanted 
mesh may require additional surgery that may or may not correct the 
complications” (18). The updated statement issued in 2011 had a significant 
distinction: “serious complications associated with surgical mesh for 
transvaginal repair of POP are not rare”, and it was plainly stated that POP 
repair with mesh is “not clearly more effective than traditional non-mesh 
repair”. Indeed, mesh may expose patients to “greater risk” compared to 
traditional surgical approach (19). This severed to separate mesh used for 
POP compare to mesh used for SUI surgeries. However, the FDA did not 
declare special concern related to SUI surgeries using synthetic mesh, and 
most complications were related to POP surgeries using mesh. That being 
said, the FDA in 2013 stated explicitly “that safety and effectiveness of 
multi-incision slings is well established in clinical trials that followed 
patients for up to one-year” (20), and there were no recommendations or 
advice to chose non mesh-based intervention for SUI. None of the FDA 
communications or notifications regarding mesh use in pelvic reconstructive 
surgery in general was related to a recall (17). 
 
It was necessary to discus the warnings and concerns of the FDA regarding 
surgical use of mesh in pelvic surgery due to the confusion that occurred in 
both parties involved in this issue: health practitioners and patients, 
especially with the appearance of different reports and investigations in 
media and the commencement of multiple lawsuits in U.S and Canada.  
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2.2 Complications Rates in Literature 
 
 A literature search for the incidence of complications associated with 
synthetic sling use in SUI can be quit difficult. Investigators tend to report 
complications of synthetic slings that were placed during POP repair 
procedure, which can makes such results confusing. Another challenging 
issue is the ambiguous terminology of different complications used in 
different studies and reviews. For example, voiding dysfunction can be 
defined as the inability to void completely, inability to empty the bladder 
comfortably, or dysuria, which is confusing, and many articles do not 
specify the definition they use. Likewise, pain may be reported post 
operatively as complication; most articles didn’t use a pain scale either 
initially or in follow up.  
 
Characteristics of patients reviewed are another limitation when assessing 
incidence rate of sling-related complications, as most of the patients were 
not homogenous in their surgical history, and several studies did not 
differentiate between patients who underwent sling surgery as primary anti-
incontinent surgery and those who had recurrent SUI treated with previous 
sling or non-sling procedure. All those factors may contaminate the true rate 
of complications of synthetic sling surgery as a variable, and influence the 
analysis of true factors likely causing those complications.  
 
One last issue about the true incidence of complications is the actuality of 
reported complications in literatures. Many centers and health practitioners 
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in the world do not publish articles or studies about synthetic sling 
complications for different reasons; they would just report them to the local 
authorities according to established protocols in their administrative setting. 
This may present literature with an inaccurate complications rate, which was 
demonstrated in one study that compared complications rate reported in 
literature between 2001 and 2005 with the rate found in FDA’s 
Manufacturer and User Device Experience (MAUDE) database (21). There 
was significant discrepancy between the two rates with the one reported in 
MAUDE higher than those published in literature. The authors explained 
this difference with the fact that some complications related to urethral and 
bladder perforation can present with mild urinary symptoms, which make 
them less likely to be reported (21).  
 
 
2.3 Perioperative and Immediate Postoperative Complications 
 
As mentioned previously, synthetic sling- related complications could be 
categorized in relation to their clinical presentation timing to perioperative 
or immediate postoperative complications, and late postoperative 
complications. We’ll discus here incidence rate of perioperative and 
immediate postoperative complications.  
 
2.3.1 Bladder Perforation 
 
 A meta-analysis of randomized controlled trials that compared tension-free 
midurethral tapes to other surgical procedures carried out by Novara et al in 
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2008 showed that retropubic approaches was more likely to cause bladder 
perforation (22). This was evident in other studies (14) (23), and several 
systematic reviews (24) (25) (26). Novara et al did update their systematic 
review two years later and found the same result regarding bladder 
perforation risk (27). Stanford et al found in their review of all urethral 
slings complications that overall incidence of abdominal and pelvic organ 
injury including bladder was 3.3% (28), however, intraoperative bladder 
perforation rates of up to 24% have been reported (29).  
Incidence of bladder perforation/injury in retropubic approaches in general is 
low, as reported by Kuuva et al in their nationwide analysis of TVT sling 
procedure and Abouassaly et al in a multi-institutional review as 3.8% and 
5.8%, respectively (30) (31).  
 
2.3.2 Urethral Injury  
 
The urethra is also at risk of injury during SUI corrective surgery using a 
synthetic sling. One review of urethral injury rate showed no statistically 
significant difference in its incidence between retropubic and transobturator 
approaches (29). However, a meta-analysis done by Schimpf et al. showed 
that urethral injury cases were fewer in the transobturator approach (25). 
Authors in the former review reported a median incidence rate of urethral 
injury at both retropubic and transobturator approaches to be 0.88% (range 
0.1-5.5%) and 1.09% (range 0.0-2.5%), respectively. They identified risk 
factors like previous pelvic surgery, infection, radiotherapy, and experience 
of the surgeon. Along with their literature review, authors also reported 14 
cases of urethral injury identified in their center, and they concluded based 
on their criteria and findings that fistula, diverticulum formation and 
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symptomatic outflow obstruction are serious squeals to urethral injury, and 
recurrent or persistent stress urinary incontinence is common, for which they 
recommended cystourethroscopy as part of all mid-urethral sling procedures. 
 
2.3.3 Major Vascular Injury 
  
Major vascular injury during synthetic sling surgery can be serious, although 
rare in occurrence. Vascular injuries involving large arteries like the external 
iliac, femoral, obturator, epigastric and inferior vesical have been reported 
(14). A review of the FDA MAUDE database between 2001 and 2005 
revealed 36 cases of major vascular injury including three deaths (21). 
Incidences between 0- 0.1% have been reported in four national registries of 
synthetic slings procedures (32). Kuuva et al in their evaluation of 1455 
cases reported an incidence of 0.07% for major vascular injury (30).  
 
In a study to avoid vascular injury, Muir et al reviewed and described the 
vascular anatomy of lower pelvis in relation to insertion of tension-free 
vaginal tape (33). They used fresh frozen cadavers in their study, and they 
performed tension-free tape insertion in three different planes in relation to 
needle passage, then they evaluated distance to different vessels. The mean 
distance from the tape needle to the obturator vessels was the closest: 3.2 cm 
(range 1.6–4.3 cm). The mean distance from the tape needle to the 
superficial epigastric vessels was 3.9 cm (range 0.9–6.7); to the inferior 
epigastric vessels, 3.9 cm (range 1.9–6.6 cm); and to the external iliac 
vessels, 4.9 cm (range 2.9–6.2 cm). When the needle was directed 6 cm 
lateral to the mid–biceps brachii muscle (according to planes already 
constructed), the external iliac vein was punctured.  
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2.3.4 Voiding Dysfunction 
 
Voiding dysfunction is a common complication after synthetic sling surgery, 
and symptoms can be related to storage phase or voiding phase. Reviewing 
the literature for voiding difficulty is challenging because of its inconsistent 
definition among different studies. Some studies and reviews differentiate 
between incomplete emptying (as manifested by post void residual more 
than 100 ml) and complete retention. Other studies don’t do that and only 
report, “voiding dysfunction” without clear definition. This makes 
evaluation of its true incidence a very difficult target. Added to this, the 
heterogeneity of patients reviewed in their past surgical history makes it 
doubtful to attribute postoperative voiding difficulty to the sling procedure 
solely.  
 
The incidence of voiding lower urinary tract symptoms (LUTS) varies 
between 3.3% up to 54.9% in randomized controlled trials assessing 
different surgical kits in the retropubic approach (22). In an analysis of 404 
cases of SUI who underwent tension-free vaginal tape procedure in 
prospective multicenter study, voiding difficulty was noticed in 4% of 
patients (34). Abouassaly et al noticed in their multi-institutional review that 
19.7% of patients who underwent tension-free tape had a urinary retention 
for more than 24 hours postoperative (31), almost two-thirds of them were in 
retention for less than 48 hours, and the other one-third were treated with an 
indwelling catheter or clean intermittent catheterization for a mean period of 
22 days. In seven patients the tape was released to treat the retention, and it 
was sectioned in three. Kuuva et al reported low incidence rates of both 
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minor voiding difficulty and complete urinary retention as 7.6% and 2.3%, 
respectively with retropubic approaches of sling placement (30). Difficulty 
in emptying and/or retention were the main presenting symptoms in 9 out of 
21 cases of retropubic sling procedure at a tertiary referral center (21). Cases 
varied in their presentation time; 6 cases presented immediately 
postoperatively, and the other 3 presented in less than two weeks. 
 
Several comparison studies and meta-analysis found no statistical/clinical 
significance in immediate postoperative voiding difficulty between 
retropubic and transobturator approaches of synthetic sling placement (24) 
(25) (27) (35) (36). Reported rates of postoperative obstruction after 
synthetic slings surgery in general range from 1.9% to 19.7% (14). In one 
review by Petri et al, however, obstruction was noted in 48% of patients 
presented with complications (13). Interestingly, analysis of 233 cases 
underwent TOT sling procedure with 27 months follow-up found no 
difference in term of urinary retention earlier in postoperative period 
between women who had sling surgery compared to women who had sling 
surgery and another surgical procedure (37). 
 
2.3.5 Other Complications 
 
Other immediate postoperative complications like UTI, groin pain, 
hematoma and wound related complications were also reported in the 
literature. Table 2.1 summarizes some of those complications reported in 
selected articles. 
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Table 2.1 Non-frequent Reported Complications Related to Synthetic Slings in 
Different Studies 
 
Reference No. Of 
Case 
Follow- 
up 
(Months) 
Hematoma 
 (%) 
Groin/ 
Thigh 
pain (%) 
Wound 
related  
UTI 
(%) 
Kaelin-
Gambirasio 
et al (37) 
233 
(TOT) 
27 0.4 NR NR NR 
Petri et al 
(13) 
359  
(Suburet
hral 
Slings) 
> 120 2 2.5 1.6 10 
Abouassaly 
et al (31) 
241 
(TVT) 
NR 1.9 NR 0.4 12 
Meschia et 
al (34) 
404 
(TVT) 
35 1.5 NR 0.5 NR 
Neuman M 
(38) 
300 
(TVT-
O) 
4-24 NR NR NR 0 
Karram M  
(39) 
350 
(TVT) 
48 1.7 NR 0.9 10.9 
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2.4 Late Postoperative Complications 
 
Long-term follow-up of patients who underwent synthetic sling surgery for 
SUI may help to detect late postoperative complications as soon as they are 
evident, so proper medical intervention can be initiated immediately. Two 
complications commonly reported in long-term follow-up after synthetic 
sling surgeries are discussed here. 
 
2.4.1 De novo Urgency and Urge Incontinence 
 
 De novo urgency was among the commonest long-term complications 
reported after synthetic sling surgery for SUI. It was noted with other 
irritative LUTS after synthetic sling surgery. It’s incidence varied between 0 
to 25.9% in different studies(14). Recent meta-analysis showed that 
postoperative overactive bladder (OAB) symptoms were more common in 
patients who had retropubic slings (25). Novara et al reported similar 
findings in their updated systematic review, although when they did meta-
analysis of high-quality RCTs no statistical significance was noted (27). 
Urgency and/or urge incontinence can be an early sign of mesh 
misplacement, whether in urethra, bladder neck, or bladder itself. Deng et al 
in their review of complicated cases post synthetic slings procedures found 
mesh in the urethra and/or bladder in ten cases presented with irritative 
LUTS (21). Holmgren et al did another review that included 463 women 
who had TVT for genuine SUI for de novo urgency incidence and found it to 
be 14.5% (40). Based on their analysis of all women criteria, they found that 
older age, parity, and history of cesarean section were significant risk 
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factors. Petri in his review of 359 cases of synthetic sling surgery 
complications concluded that de novo OAB seems to be the commonest 
complication with rate of 54% (13). He did recommend changes in the new 
IUGA-ICS classifications of complications to adapt this complication. 
 
2.4.2 Vaginal Erosion 
 
Vaginal erosion is defined as “the presence of foreign material (sutures, 
sling material) within the vagina after vaginal wound healing” (41). It used 
to be reported more commonly, which could be attributed to the types of 
meshes used initially and their mechanical properties. Also, types of surgical 
devices that were available in the market previously contributed to higher 
rates of erosion, for which they were recalled because of their overall higher 
risk of complications (14) (27) (37). Lack of cumulative experience with 
both proper wound dissection and proper placement of tape are other 
influencing factors.   
 
A prospective study by Chen et al analyzed the possible risk factors for 
vaginal tape erosion after synthetic sling surgery in 233 women who 
underwent sling surgery for SUI (41). They reported erosion in 6 patients, 
and among clinical risk factors they assessed for erosion only diabetes 
mellitus (DM) was a significant one. Thus, they advised counseling women 
with DM that vaginal erosion is a possible complication after tape 
procedure.  Another analysis of 233 women who underwent TOT procedure 
found that age, body mass index (BMI), and concomitant pelvic procedure 
were not statistically significant risk factors for erosion (37). Petri et al in 
their review of 359 cases with synthetic sling related complications reported 
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vaginal exposure in 68 patients (13), and it was among the commonest three 
complications in that group.  
 
Two meta-analysis reviews compared the retropubic to the transobturator 
approach in vaginal erosion risk, and found increased risk with the 
transobturator approach (24) (25). On the other hand, another meta-analysis 
done in 2008 and updated in 2010 found no statistically significant 
difference between the two approaches (22) (27). Tommaselli et al did a 
recent meta-analysis, and found that transobturator approach in synthetic 
sling surgery was associated with increase risk of both vaginal injury and 
erosion (26). This discrepancy could be explained by the criteria of the 
RCTs included in those meta-analyses. Another possible reason is the 
inclusion of studies reported on use of older surgical device for 
transobturator insertion of synthetic sling, which was known to be associated 
with a higher incidence of erosion.  
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3     Methodology 
 
The purpose of our study was to: 1) estimate the incidence of synthetic sling 
removal after synthetic sling surgery for SUI, 2) assess the possible impact 
of surgical volume and specialty of the provider surgeon on this incidence, 
and, 3) to evaluate other risk factors for sling removal.  
 
 
3.1 Study Design 
 
 We conducted a retrospective population-based cohort study examining all 
adult women who underwent a SUI synthetic sling procedure in the period 
between April 2002 and December 2012 (fiscal year 2002/03 to 2011/12). 
Our study was conducted in Ontario, Canada, a province of over 13 million 
residents (42) with nearly universal health care access, and coverage of 
government funded health care system. No patient consent was required as 
our data were administrative in nature. The research ethics board at 
Sunnybrook Hospital, Toronto, Canada, approved the study.  
 
 
3.2 Data Source 
 
Data regarding the cohort, outcome, and different variables measured were 
collected using linked health care databases via Institute for Clinical 
Evaluative Sciences (ICES), which is a not-for-profit research institute made 
up of a community of research, data and clinical experts, and a secure and 
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accessible set of Ontario's health-related data such as population- based 
health surveys, as well as clinical and administrative database (43). 
 
Canadian Institute for Health Information (CIHI) was one source of data in 
our study. It manages a number of databases as part of its contribution to the 
health care system in Canada. Discharge Abstract Database (DAD) and 
Same Day Surgery (SDS) are two of those databases, and were used to 
identify our cohort with their primary and secondary diagnosis, day- surgery 
procedures, discharges, and death records. 
 
The Ontario Health Insurance Plan (OHIP) database was also used in our 
study. The ministry of health maintains it and it has records for all 
physicians’ payments to Ontario doctors.  It also includes all claims 
submitted whether services were on an inpatient or out patient basis. 
 
Data quality measures have been carried out to ensure a high-quality 
administrative data in all three data sources. One measure was through 
conducting a review of published and unpublished studies in Canada to 
assess the completeness of data and the level of agreement across different 
databases (44) (45). Quality of data was assessed through three criteria: 
Completeness of the data, agreement of information when data from one 
database was compared to the same information obtained from another 
database, and agreement of diagnosis with experts’ opinion. After this 
review that was done in 2000, it was concluded that demographic 
information on patient age, sex and residence was complete and reliable, and 
there were a high levels of agreement on specific surgical procedure codes 
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found in hospital discharge data and medical claims (45). Also, billing 
claims for physician services provided complete capture of procedure codes. 
 
 
3.3 Patients Population 
 
All adult women above the age of 18 years who underwent SUI synthetic 
sling procedure in Ontario in the period of April 2002 to December 2012 
were identified and included in our study. Canadian Classification of Health 
Intervention (CCI) codes from the CIHI-DAD/SDS database were used to 
identify the patients (Appendix B). CCI code system is the standard coding 
system used for classification of health-related interventions in Canada, and 
it is the companion classification system to International Classification of 
Disease (ICD) in its 10th revision (46). 
 
The CCI coding system was revised more than once through adding new 
codes and updating existing ones to accommodate new procedures and 
surgical approaches. These changes were considered in identifying cohort 
patients in our study. Also, as different surgical kits had different entry times 
to the markets, possible CCI codes for all different kits were assessed, 
revised and included during data collection. 
 
We set a look back window of five years prior to index date to prevent 
contamination of our primary outcome and to ensure completeness and 
validity of the data. Certain exclusion criteria (Table 3.1) were applied to 
cohort patients using OHIP and CCI codes for the same above reasons. Prior 
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pelvic surgical interventions using meshes like anti incontinence surgery or 
POP repair can influence the result of index synthetic sling surgery, thus 
affect its complications whether in nature of complication or its prevalence. 
So, such cases were excluded. However, patients who underwent 
simultaneous or subsequent non-mesh based POP surgery were included in 
the study to monitor the effect of concomitant pelvic surgery on SUI 
surgery.  
 
Table 3.1 Exclusion Criteria in Cohort Patients 
Exclusion Criteria  
Prior incontinence surgery 
Prior vaginal prolapse repair surgery 
Additional SUI/POP surgery performed within 1 week of index event 
Neurogenic diagnosis 
 
As patients were identified through linked administrative databases, 
additional exclusion criteria were applied for data cleaning to ensure the 
highest quality of data. For examples, patients with missing or invalid health 
record number, missing or male sex, and missing birth date were excluded. 
In addition, patients who were not permanent residents in Ontario were 
excluded to ensure best longitudinal follow up for cohort.  
 All these exclusion criteria were assessed and applied using CCI/CCP and 
OHIP codes as mentioned previously. Such codes could be traced back to 
1992, when a well-established electronic coding system using CCI was 
available and traceable.  
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Index date was assigned as the date of SUI surgery using synthetic mesh, 
and observation of cohort was continued until death, first occurrence of an 
outcome, date of last contact of patient with health care system as follow up 
plus one year, or the end of the study, that was determined by March 31st 
2013.  
 
 
3.4    Primary Outcome 
 
The primary outcome was defined as the first reoperation for SUI mesh-
related complications. CCI codes were used in identifying outcome, and all 
possible codes related to mesh complications surgeries were included. For 
example, codes related to removal of foreign body in urethra, division, 
extraction of foreign body in vagina, and urethrolysis were included. Also, 
codes describing endoscopic treatment of foreign body or mesh encrustation 
in bladder were assessed and included. In an attempt to include all 
operations related to SUI mesh sling complications in the cohort, CCI codes 
specific to management of bladder neck slings were included, like removal 
of internal device (i.e. sling), taking into considerations different approaches 
(like open, vagina, endoscopic). Different CCI codes used to define primary 
outcome are outlined in Appendix C.  
 
When two outcomes were found in one patient, the first recorded one was 
marked as the primary outcome. Any CCI code with less than 6 in number of 
patients (i.e. number of patients experienced outcome with that CCI code) its 
actual value was not reported for privacy issues. 
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3.5 Primary Exposures 
 
Surgeon volume and surgeon specialty were identified as primary exposures 
of interest in our study. Surgeon volume was defined as the number of 
synthetic sling procedures for SUI done per year, which is assessed by the 
hospital administration on a yearly basis. Surgeons are categorized in 
databases as high-volume and low-volume providers. High-volume surgeons 
are defined as being above or at the 75th percentile for sling surgery number 
in a given year, and surgeons’ status could change from high to low-volume 
category and vice versa; surgical volume was checked on a yearly basis. 
This was considered and included in our study data, and it was tracked via 
CIHI-DAD/SDS databases. 
Surgeon specialty was determined as urologist, obstetrician/gynecologist, or 
undetermined. It was also accessed via CIHI-DAD/SDS database. 
Undetermined group of surgeons who did the synthetic sling surgery were 
created after failure to specify their specialty through database.  
 
 
3.6 Secondary Exposures 
 
As our study was designed to be both a descriptive and analytic 
observational cohort with a large number of patients, we also evaluated the 
effect of other factors on the incidence of reoperation for SUI sling-
complications. The number of implanted slings to treat SUI was evaluated as 
one of the secondary exposures. So, we identified all patients who had two 
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or more synthetic mesh implant to treat SUI and we assessed their risk for 
higher incidence of complication- related surgery. 
 
Patients with known risk factors for synthetic sling complications were 
evaluated as one group. Those factors are: previous urinary fistula, urethral 
diverticulum, pelvic radiation and urethral injury. Diagnosis of these 
conditions was identified by CCI codes in the cohort patients. They were 
examined as a secondary exposure. 
 
The setting of health facility that sling was implanted in was evaluated as 
possible risk factor for sling complications occurrence. Hospitals were 
categorized as academic and community hospitals, and patients’ initial sling 
implant was grouped accordingly.  
 
Other risk factors that might affect the incidence rate of reoperation after 
SUI sling surgery included: age, concomitant pelvic surgeries at the time of 
sling implant without mesh (like POP repair), obesity, and DM. They were 
considered as secondary exposures and evaluated independently. 
 
All those covariates were defined using different defining codes from both 
databases of OHIP and CIHI-DAD/SDS (Appendix D). A summary of both 
primary and secondary exposures evaluated in our study is obtained in Table 
3.2. 
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Table 3.2 Primary and Secondary Exposures 
Primary Exposures 
Surgeon Surgical Volume 
Surgeon’ Specialty 
Secondary Exposures 
Age  
Concomitant surgeries (Hysterectomy, POP repair) 
DM 
Obesity 
High risk patients (H/O urethral diverticulum, urethral injury, urinary fistula, pelvic 
radiation 
Multiple synthetic sling implant for SUI 
Academic hospitals 
 
 
3.7. Statistical Analysis 
 
As mentioned previously, one of our objectives was to evaluate specific 
factors (as an independent variables) on the rate of reoperation for SUI 
complications. An important variable was surgeon’ surgical volume, so, we 
subcategorized patients into two groups and reported baseline characteristics 
based on high and low volume surgeons. Baseline characteristics are 
reported in Table 3.3. Those criteria were reported in either numbers with 
corresponding percentage or medians with their corresponding interquartile 
range (IQR). IQR was used as out measure of spread of our data points. 
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Table 3.3 Reported Baseline Characteristics of Patients  
Characteristics of Cohort Patients 
Age 
Obesity (BMI > 40) 
DM 
Concomitant hysterectomy 
Prior hysterectomy 
Prior non-mesh-based surgery for POP 
Concomitant non-mesh-based surgery for POP  
> 1 Synthetic sling implant for SUI 
High risk patients 
Fiscal year of cohort entry (Index date) 
Surgeon specialty (Urology, Obstetrics/gynecology/unknown) 
Teaching hospitals 
No. Of health care resources used 1 year before synthetic sling implant for SUI 
Death after index date  
Emigration 
 
Comparability of the two groups of cohort patients on their baseline criteria 
was carried out using standardized differences of the mean (SDM), which is 
more informative than traditional hypothesis testing, especially in large 
sample/group size of observational research as our study had (47). To 
measure strength of any association between surgical volume and different 
enlisted baseline criteria, a standardized difference of more than 10% (or 
0.1) was considered significant (48).  
 
We conducted a multivariable survival analysis as primary analysis for our 
data, and we included surgeon’ volume, surgeon’ specialty, high-risk 
patients, and the multiple mesh implanted group. Our study examined the 
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cohort patients with different index dates over ten years (i.e. different entry 
points) and different time period to complication surgery (primary outcome). 
For which, hazard ratio (HR) with confidence interval (CI) was calculated to 
estimate the risk of primary outcome over the study time period.  CI of 95% 
was reported for clinical significance.  
 
Multivariable analysis was run using the PROC PHREG procedure in SAS 
software (version9.3; SAS Institute Inc.), and a Cox proportional hazards 
regression model was used to assess the effect of different covariates on the 
outcome over time. We adjusted for age, obesity, diabetes, concomitant 
hysterectomy, prior hysterectomy and/or non-mesh-based surgery for POP, 
concomitant non-mesh-based surgery for POP and hospital type. Cumulative 
incidence rate of outcome was calculated using Kaplan- Meier survival 
analyses, and Cochrane –Armitage test was used to assess the linear trend of 
outcome and significant changes in the 1-year event rate over time.  
 
 
 
 
 
 
 
 
 
4    RESULTS 
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4.1 Baseline Characteristics 
 
We identified 61,876 women who underwent synthetic sling implant for SUI 
(Figure 4.1). 1,989 patients were excluded according to our predefined 
exclusion criteria listed in table 4.1. A final cohort of 59,887 patients was 
reviewed and analyzed, out of whom 1,740 patients died and 915 patients 
were lost to follow up (identified by date of last contact with health care 
system plus 1 year). We reached the end of the study with 55,925 patients. 
The number of patients enrolled per fiscal year is outlined in figure 4.2 (as 
our study endpoint was predetermined to be December 31st 2012, and fiscal 
year starts on April 1st and ends on March 31st, the rest of data for 2012 were 
extrapolated from the period January 2013-March 2013 based on available 
data of the first 9 months), and a steady increase in patients’ number is 
observed, likely due to the increase in popularity of synthetic slings as 
minimally invasive procedure to treat SUI. Another possible reason is the 
practice of “prophylactic MUS surgery” when performing POP repair.  
 
Median age of patients was 52 years (IQR, 45-63), and median follow-up 
was 4.4 years (IQR, 2.3-6.8). Surgical procedures were done by total of 
1,068 surgeons, out of whom 625 were gynecologists (58.5%), 293 were 
urologists (27.4%), and 150 (14%) were undetermined. Patients were 
categorized according to surgical volume of their operating surgeon into two 
groups (Table 4.2). High-volume surgeons were defined by being at the 75th 
percentile or above for procedures performed for SUI yearly. They operated 
on 44,140 (73.7%) patients (Figure 4.3). 
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61,876 Patients
All slings cases
1,740 Patients
Death
59,887 Patients 
Reviewed
915 Patients
DOLC+1year
1,307 Patients
Primary 
Outcome
55,925 Patients
Reached 
end of F/U
1,989 
Patients
Excluded
Table 4.1 Cohort Patients’ Exclusion Criteria 
Exclusion Criteria No. Of patients 
Age < 18 years or > 100 years 9 
Male/Missing gender  507 
Non Ontario residence 37 
Use of vaginal mesh for prolapse prior to 1st of April 2002 594 
Use of vaginal mesh for prolapse after 1st of April 2002 507 
Prior use of mesh for SUI  56 
Missing hospital institution  279 
 Total = 1989 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Flow Chart of Cohort Patients  
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Figure 4.2 Number of Patients Who had Mesh-based SUI Surgery Per Year between 
2002- 2012. Note that number of patients in 2012 was derived from combined data 
from both fiscal years 2012 and 2013 (see text) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Cohort Patient’s Distribution According to their providers’ surgical 
volume. 
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Table 4.2 Baseline Criteria of Patients in Relation to Surgeon’ Volume 
 High -Volume 
Surgeons a 
(n=44140) 
Low-Volume 
Surgeon 
(n=15747) 
Standardized 
Difference of 
the Meanb  
Age, median (IQR), years 53 (45-63) 52 (45-63) 0.02 
BMI >40, number (mean) 1976 (4.5) 698 (4.4) 0 
Diabetes mellitus, number (mean) 5222 (11.8) 2036 (12.9) 0.03 
Concomitant Hysterectomy, 
number (mean) 
5061 (11.5) 2603 (16.5) 0.14 
Prior Hysterectomy, number (mean) 3633 (8.2) 1329 (8.4) 0.01 
Concomitant non-mesh-based 
surgery for POP, number (mean) 
13115 (29.7) 4743 (30.1) 0.01 
Prior non-mesh-based surgery for 
POP, number (mean) 
2386 (5.4) 805 (5.1) 0.01 
> 1 Synthetic sling implant for SUI, 
number (mean) 
900 (2.0) 352 (2.2) 0.01 
High risk patients c, number (mean) 54 (0.1) 19 (0.1) 0 
 
Fiscal year of cohort entry (index date), number (mean) 
      2002  1917 (4.3) 668 (4.2) 0 
      2003  2664 (6.0) 859 (5.5) 0.02 
      2004  3199 (7.2) 1005 (6.4) 0.03 
      2005  4056 (9.2) 1251 (7.9) 0.05 
      2006  4144 (9.4) 1584 (10.1) 0.02 
      2007  4727 (10.7) 1669 (10.6) 0 
      2008  5218 (11.8) 1759 (11.2) 0.02 
      2009  5177 (11.7) 2055 (13.1) 0.04 
      2010  4836 (11.0) 1859 (11.8) 0.03 
      2011  4969 (11.3) 1835 (11.7) 0.01 
      2012  3233 (7.3) 1203 (7.6) 0.01 
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 High -Volume 
Surgeons a 
(n=44140) 
Low-Volume 
Surgeon 
(n=15747) 
Standardized 
Difference of 
the Meanb  
Surgeon specialty  
    Urology number (mean) 18946 (42.9) 6648 (42.2) 0.01 
    Obstetrics/gynecology 25133 (56.9) 8837 (56.1) 0.02 
    Unknown number (mean) 61 (0.1) 262 (1.7) 0.17 
Teaching/academic hospital  12762 (28.9) 2562 (16.3) 0.30 
 
No. Of health care resources used 1 year before synthetic sling implant for SUI 
number (IQR) 
   Family Physician visits, 
       
6 (3-9) 6 (3-9) 0.05 
   Urology or Gynecology   
       Visits number (IQR) 
2 (1-3) 3 (2-4) 0.26 
    Hospital admissions 0 (0-0) 0 (0-0) 0.04 
Death after index event 1289 (2.9) 485 (3.1) 0.01 
Emigration 683 (1.5) 232 (1.5) 0 
Abbreviations: IQR, interquartile range; BMI, body mass index (calculated as weight in 
kilograms divided by height in meters squared); POP, pelvic organ prolapse. 
a High volume surgeon is defined to be at or above the 75th percentile for mesh implants 
for SUI in a given year. 
b A value of greater than 10% (0.1) is considered a meaningful difference between the two 
groups. 
c Includes patients with fistula, urethral diverticulum, urethral injury, or post radiotherapy. 
 
 
Significant differences between high and low-volume surgeons appear in 
their clinical practice. High-volume surgeons (urologists or gynecologists) 
saw patients less frequently before their SUI sling surgery (median, 2 [IQR, 
1-3] vs. 3 [IQR, 2-4] visits; standardized difference, 0.26). They also were 
less likely to do concomitant hysterectomy with SUI surgery (11.5% vs. 
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16.5; standardized difference, 0.30), and they were more likely to do the 
procedure in academic hospitals (28.9% vs. 16.3%; standardized difference, 
0.30).  
 
 
4.2 Primary Analysis 
 
A total of 1307 women (2.2%) had the outcome, (removal or revision of 
their mesh implant for SUI). Their distributions according to their provider’ 
surgical volume and specialty is illustrated in figures 3 and 4. The median of 
time between original mesh-based procedure for SUI and removal date 
among the 1307 patients was 0.94 (IQR, 0.35-2.49) years (Table 4.3).  
 
 
 
Figure 4.4 Description of Patients with Outcome in Relation to Their Provider’ 
Surgical Volume 
890
417
Patients operated by
High surgical volume
providors
Patients operated by
Low surgical volume
providors
 53 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Description of Patients with Outcome in Relation to Their Provider’ 
Specialty  
 
Table 4.3. Mesh Revision/ Removal After Mesh-Based Surgery for SUI 
 Entire Cohort 
(n=59,887) 
Duration of follow-up, median, (IQR), years 4.43 (2.35-6.88) 
Total follow-up, person-years 282,801 
Outcome, No. of patients, %  1307 (2.2) 
Time from index date to outcome, median (IQR), 
years 
0.94 (0.35-2.49) 
Event rate per 1000 patient-years of follow-up  
(95% CI) 
4.62 (4.38-4.88) 
 
Calculation of cumulative incidence rate of outcome showed steady increase 
over 10 years from 1.17 (95% CI, 1.09-1.27) at year 1 post index date to 
3.29 (95% CI, 3.05-3.53) at 10 years post index date. Table 4.4 shows the 
cumulative incidence rate by years of follow up.  
584
712
11
Patients operated by
Urologists
Patiente operated by
OB/GYN
Patients operated by
Others
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Unadjusted analyses of patients who underwent revision or removal of mesh 
showed that low-volume surgeons had a 37% (p < 0.0001) increase in 
relative risk for mesh removal or revision in their patients compared to high-
volume surgeons (Table 4.5). However, there was no significant difference 
in rate of revision or removal of the mesh between gynecologists and 
urologists (RR, 0.92; 95%CI, 0.82-1.02). Table 4.6 shows the unadjusted 
analyses of patients who underwent mesh removal or revision in relation to 
their provider’ specialty. 
 
Table 4.4 The Cumulative Incidence Rate of Mesh Revision/ Removal After Mesh-
Based SUI Surgery 
 
 
Year 
No. of patients   
At the beginning 
of follow-up 
 
 
Censored 
 
 
Patients with 
outcome 
 
 
Cumulative Incidence 
(95%CI) 
1 5 59,887 4563 681 1.17 (1.09-1.27) 
2 54,643 7042 234 1.63 (1.52-1.74) 
3 47,367 6795 118 1.90 (1.78-2.020 
4 40,454 7267 83 2.12 (2.00-2.46) 
5 33,104 6955 64 2.33 (2.20-2.46) 
6 26,085 6210 48 2.54 (2.39-2.69) 
7 19,827 5504 28 2.69 (2.53-2.85) 
8 14,295 5013 25 2.90 (2.72-3.08) 
9 9257 3874 16 3.11 (2.91-3.31) 
10 5367 3134 7 3.29 (3.05-3.53) 
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Table 4.5 Mesh Revision/ Removal After Mesh-Based Surgery for SUI Based on 
Provider’ Surgical Volume 
 High-volume 
Surgeons 
(n=44,140) 
Low-volume 
Surgeon 
(n=15,747) 
Duration of follow-up, median, (IQR), years 4.5 (2.38-6.96) 4.24 (2.24-6.68) 
Total follow-up, person-years 210,483 72,318 
Outcome, No. of patients, % 890 (2.0) 417 (2.6) 
Time from index date to outcome, median 
(IQR), years 
0.94 (0.34-2.59) 0.93 (0.35-2.38) 
Event rate per 1000 patient-years of follow-up 
(95% CI) 
4.23 (3.96-4.52) 5.77 (5.24-6.35) 
Unadjusted risk ratio (95% CI) 1 (Reference) 1.37 (1.17-1.49) 
 
Multivariable analyses showed similar results regarding primary exposure 
(Table 4.7). With Hazard ratio of 1.37 (95% CI, 1.21-1.55; P value <0.01), 
patients who were operated on by low volume surgeon were more likely to 
have a later surgery to remove or revise the mesh. No significant difference 
was found between gynecologists and urologists in such risk (HR, 0.94; 
95%CI, 0.83-1.08; P value, 0.38).  
As we explained in our methodology, we adjusted for age, obesity, diabetes, 
concomitant hysterectomy, prior hysterectomy and non-mesh-based surgery 
for POP, concomitant non-mesh-based surgery for POP and hospital type. 
Those factors were considered as potential confounders. 
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Table 4.6 Mesh Revision/ Removal After Mesh-Based Surgery for SUI Based on 
Surgeon’ Specialty  
 Urologists 
(n=25,594) 
Gynecologists 
(n=33,970) 
Duration of follow-up, median, (IQR), years 4.96 (2.68-7.46) 4.10 (2.13-6.38) 
Total follow-up, person-years 131,036 150,074 
Outcome, No. of patients, % 584 (2.3) 712 (2.1) 
Time from index date to outcome, median 
(IQR), years 
1.0 (0.32-2.82) 0.90 (0.37-2.23) 
Event rate per 1000 patient-years of follow-
up (95% CI) 
4.46 (4.11-4.83) 4.74 (4.41-5.11) 
Unadjusted risk ratio (95% CI) 1 (Reference) 0.92 (0.82-1.02) 
 
 
Table 4.7 Multivariable Survival Analysis to Assess Patients and Surgeon Risk 
Factors For Removal or Revision of Synthetic Sling after SUI 
Variable HR (95 CI%) P value 
Surgeon Volume 
     High 
     Low  
 
1 (Reference) 
1.37 (1.21-1.55) 
 
 
<0.01 
Surgeon Specialty 
     Urology 
     Gynecology 
 
1 (Reference) 
0.94 (0.83-1.08) 
 
 
 0.38 
Multiple mesh-based 
procedures for SUI 
 4.73 (3.62-6.17) <0.01 
High risk patients a 0.58 (0.08-4.13) 0.59 
Age per 10 years increase  0.86 (0.82-0.92) <0.01 
Obesity 0.82 (0.62-1.10) 0.19 
Diabetes mellitus  1.11 (0.94-1.32) 0.22 
Concomitant 1.24 (1.08-1.42) <0.01 
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Variable HR (95 CI%) P value 
hysterectomy 
Concomitant non-mesh-
based surgery for POP 
0.80 (0.66-0.97) 0.02 
Academic/ Teaching 
hospital 
1.18 (1.02-1.36) 0.03 
Abbreviations: SUI, stress urinary incontinence; POP, pelvic organ prolapse. 
 a Includes patients with history of fistula, diverticulum, urethral injury, or radiotherapy 
 
As per our secondary exposures, patients at higher risk for sling removal or 
revision were grouped together and analyzed. We had a total of 73 patients 
with the following high-risk features: history of urethral diverticulum or 
injury, history of urinary fistula, and history of prior pelvic radiotherapy. 
They did not show increase risk for sling removal or revision surgery (HR, 
0.58; 95%CI, 0.08-4.13)  
 
Concomitant hysterectomy at the time of sling implant for SUI did increase 
patient’ risk for reoperation for sling revision or removal as outlined in table 
4.7. However, non-mesh-based POP repair decreased the risk of reoperation 
for a later complication, (HR, 0.80; 95%CI, 0.66-0.97). 
 
A total of 1,252 patients had multiple synthetic slings implants for SUI, and 
multivariable analysis showed significant increase in their risk for mesh 
removal or revision (HR, 4.73; 95%CI, 3.62-6.17; p <0.01).  
Finally, patients who had their SUI procedure in teaching hospital were 
more likely to have their mesh removed or revised (HR, 1.18; 95%CI, 1.02-
1.36; p= 0.03).
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5   DISCUSSION 
 
 
SUI in women will remain a substantial problem with significant social and 
economical impact. Surgical intervention based on the concept of 
strengthening urethral tissue and pelvic floor muscles was tried as early as 
1900s when Von Giordano used a muscle graft to support urethra (2). 
Currently, as discussed in chapter one, synthetic sling or mesh-based 
procedure has become the gold standard management for treating SUI in 
female (1). However, this procedure is not without complications, for which 
many studies were done and lot of reviews were carried out to outline and 
predict those complications and estimate their incidence rate in different 
setups. Our study was designed to measure the incidence rate of reoperation 
for mesh-based complications and to study the effect of certain prespecified 
factors, which were hypothesized to influence the risk of complications. 
 
 
5.1 Principal Findings 
 
In our large cohort study, we found that rate of removal or revision of 
synthetic sling implanted for SUI was 2.2%, with a cumulative incidence 
rate of 3.29% at 10 years of the initial procedure. As one of important 
presumed predictors, surgeon’ specialty (urology or gynecology) was 
evaluated, and our study showed that it has no effect on rate of reoperation 
for complications. Another important factor we assessed was the surgical 
volume of the operating surgeon, which did have an effect on the rate of 
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mesh removal or revision, with low-volume surgeon having 37% higher risk 
of reoperation on their patients. Other worthwhile findings about predictive 
factors were as following; first, our study showed that implantation of more 
than one synthetic sling increased the risk of complications by almost 5 folds 
compared to single synthetic sling implantation. Second, we found that 
concomitant hysterectomy did increase the risk of reoperation for mesh-
related complications, however non-mesh-based POP surgery did not. Third, 
patients who had their operation in an academic or teaching hospital were 
more likely to have mesh-related complications. Finally, patients with 
known risk factor for following complications after implantation of synthetic 
sling, such as history of urethral injury or diverticulum, or had previous 
pelvic radiotherapy did not express more risk for sling removal or revision.  
 
 
5.2 Comparison with Previous Studies 
 
Conducting literature review for incidence rate for sling revision or removal 
after SUI surgery was challenging as most of authors reported incidence 
rates that were specific to certain reasons only like voiding dysfunction 
rather than the incidence rate in general (49). Others would only report cases 
series of sling removal due to different causes (50). One population-based 
cohort study did assess long-term incidence rate of sling revision for mesh 
erosion and urinary retention (51), and incidence rate of sling revision in 
their study was consistent with our reported one, with a cumulative risk of 
3.7% at 9 years follow-up. Another case-control study carried out in US 
examined all women who underwent midurethral sling placement for SUI 
between January 2003 and December 2013 (52). Authors reported that 2.7% 
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of their patients underwent sling revision for different reasons, which is also 
close to incidence rate in our study. 
 
As both urologists and gynecologists are involved in the management of SUI 
in females, both specialties had carried out placement of mid-urethral slings 
since synthetic sling appearance in late 1990s. Both specialties have 
different training curriculum related to pelvic surgery due to the obvious 
variation in daily practice. Studies had suggested differences between the 
two specialties in the surgical management of SUI and outcome of synthetic 
sling surgery (53), however, two studies showed no difference in incidence 
of sling revision or urological and non-urological complications (54) (53). 
Our study confirmed such finding, which emphasize the importance of 
procedure-based training rather than surgical background and training. It 
also supports the concept of similar basic surgical training programs or 
courses for trainees from both specialties in the aspect of sling-based 
surgery.  
 
Volume-outcome relationship in health care has been evaluated and assessed 
in several studies (55) (56) (57). Authors in those studies concluded that for 
a numerous surgical procedures and medical conditions, higher volume 
(whether assessed in relation to hospital or physicians) was linked to better 
health outcomes. The strongest associations were found for acquired 
immune disease syndrome (AIDS) treatment and for cancer-related 
procedures like pancreatic cancer and esophageal cancer. Also the outcome 
of abdominal aortic aneurysms surgery, and pediatric cardiac diseases 
management was related to surgical volume  (a median of 3.3 to 13 excess 
deaths per 100 cases were attributed to low volume) (56). In urology, 
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volume-outcome relationship have been also evaluated, mainly in uro-
oncology procedures (58) (59) (60) (61) (62), with similar observation 
regarding the inverse relationship between volume of surgeons or hospitals 
and outcome measured by mortality rate, hospital stay, reoperation rate, or 
complication rate. For mesh-based surgery for SUI, the role of surgeons’ 
surgical volume was not well assessed. One study assessed the surgeon’ 
volume effect on complications rate in pubovaginal sling procedures carried 
out in US (63), where authors analyzed data from1356 patients underwent 
sling procedures, and investigated differences between the two groups of 
surgeons in surgical management of SUI in form of performing concomitant 
POP at the time of sling procedure and in rate of repeat anti-incontinence 
procedures and complications. They found that high-volume surgeons were 
more likely to perform simultaneous POP at the time of sling surgery. They 
also noticed that low-volume surgeons had higher reoperation rates to 
correct prolapse during the first postoperative year. However, both groups 
had no statistically significant difference in their rate of complications. 
  
In our study, we did demonstrate a difference between high and low volume 
surgeons with a 37% increase risk for reoperation for mesh-related 
complications among low-volume surgeons. This supports the recent 
recommendations from both specialized surgeons and surgical societies of 
interest (64) (65), about the substantial need for adequate training in this 
subspecialist area and the importance of a thorough understanding of the 
relevant pelvic anatomy. Indeed, a review done by McLennan et al showed 
that a learning curve does exist for tension-free vaginal tape procedures (66). 
This was their conclusion after they evaluated 278 procedures done by 23 
senior residents, and they assessed the rate of bladder perforation among 
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patients. They found that incidence of perforation inversely related to the 
number of cases performed. This shows the effect of increased number of 
procedures performed (i.e. surgical volume) in the placement of SUI slings 
and the complications rate (in more generalized view). 
 
The assessment of different risk factors for mesh late complication after 
placement of synthetic slings was reviewed widely in the literature in 
relation to different surgical approaches and different surgical kits used. One 
important factor was the placement of another synthetic sling to treat 
recurrent SUI, and we did notice general acceptance of such practice in 
different reviews and studies (67) (68) (69) (70). However, authors of those 
studies did not investigate reoperation rate for late complication with long-
term follow-up, which we think is an important influencing factor in 
choosing appropriate management approach for recurrent SUI. In our study, 
multiple synthetic slings (more than one) were placed in more 1300 patients, 
and this increased their risk of undergoing another surgery for mesh-related 
complications by almost 5-fold. We hope that enthusiastic surgeons will 
consider our finding before they place a second or even third synthetic sling 
when managing recurrent SUI. We won’t recommend stopping this practice 
of placing multiple synthetic sling in patients who failed their primary 
surgery; we do advise careful patients selection and thorough counseling 
with them about potential risks, so patients are aware of all possible 
complications and do participate in this decision. We also agree with the 
recommendation to conduct multicenter, randomized clinical trials to look at 
the management of recurrent SUI and the tools used to assess patients before 
another surgical management (70). 
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An interesting finding in our study was the inverse relationship between age 
of patients and their risk for reoperation for mesh-related complication.  
Increased age is not considered a contraindication for mid-urethral sling 
placement for SUI; in fact a group of investigators from US analyzed data on 
national level of women underwent SUI surgery from 1979 to 2004. They 
found that the most significant increase in frequency of procedures was 
among the population of patients age >52 years (71), which was attributed to 
the fact of aging population and increase in number of women seeking care 
for incontinence. Studies comparing outcome of mesh-based surgery for SUI 
in elderly women compared to young women showed contradictory results 
(72) (73) (74) (75) (76). However, no well-conducted review with an 
appropriate long period follow-up assessed age as predictor factor for mesh-
related complication surgery. In our study, median age among cohort 
patients was 53 years, and risk for reoperation for complication was 
significantly decreased with each 10 years increment. This can be explained 
readily in the context of reasons for mesh revision or removal. Mesh erosion 
is a common reason for mesh removal, and reports of conservative 
management in literatures are sparse (2). Clinically, dyspareunia, vaginal 
discharge, and lower urinary tract symptoms are prevalent symptoms, and as 
older women tend to be less sexually active, this makes them less likely to 
experience such symptoms; they may not seek aggressive surgical 
management as a younger women might. Voiding difficulty or urinary 
retention is another important cause for mesh revision. It’s usually managed 
initially conservatively with temporary catheter drainage, clean intermittent 
catheterization and timed voiding. However, if persistent, it needs revision. 
Older women may be more tolerant of a degree of urinary obstruction 
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compared to younger women, thus prompting more revisions in the younger 
population for this reason. 
  
Concomitant hysterectomy at the time of SUI sling surgery did increase risk 
of reoperation due to mesh-related complication in our study. In the 
literature, concomitant hysterectomy at the time of sling placement for SUI 
was assessed as an influencing factor on the outcome of sling surgery, not on 
later complications, and many studies had found no such influence(77) (78) 
(79). However, the group from US who studied different predictors for sling 
revision found that concomitant hysterectomy actually decreased risk of 
sling revision (51). No other studies evaluated this variable. We think that 
both results could be explained via surgical techniques and the nature of 
tissues and their healing; however, as urologists do not perform concomitant 
hysterectomy, we think that such predictors would not affect long term 
results and complications of slings placement procedures performed by 
urologists, and deserves more assessment.  
 
An unanticipated finding in our study was the effect of facility in which 
synthetic sling was implanted in on long-term risk for reoperation for 
complication. Having sling implanted in an academic teaching hospital 
raised the risk for a later removal or revision of that sling. The role of 
teaching hospitals in training residents and medical students especially when 
they are university-affiliated centers is paramount. Surgical residents and 
students are involved with varying degrees in performing surgical 
procedures and in the care of patients. This is the argument for hiring 
clinicians with an academic background and competitive post-graduate 
training in teaching hospitals. Moreover, in the last two decades, teaching 
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hospital gained increased attention in national policy plan world-wide, and 
several studies investigated the relationship between teaching centers and 
quality of health care provided, measured by mortality rate, length of stay, 
perioperative complications, and morbidity. For example, three studies done 
in US evaluated mortality as a marker of quality of care, and it’s relationship 
to teaching status of the facility serving patients in the field of 
cardiovascular diseases (80) (81) (82), and all three studies showed lower 
mortality rate in the cases treated in teaching hospitals. Other studies 
assessed this relationship in major complex surgeries related to cancer, and 
they had similar findings (83) (84). However, when it comes to more 
confined surgeries like abdominal hysterectomy done for benign conditions 
and rectal cancer surgery, studies showed no significant difference in 
mortality between teachings versus non teaching hospitals (85) (86). In 
mesh-based surgery for SUI, no studies were found evaluating this 
relationship, apart from one done in Taiwan (87), where they assessed type 
of facility (medical center, regional, and local hospitals) on reoperation rate 
after SUI procedures, and they found no significant differences between all 
three different hospitals. This finding was attributed by the investigators to 
hospital’ volume rather than teaching status of it. In our study, such 
difference in reoperation for mesh-related complications could be explained 
by several factors. First, patients referred or treated in teaching hospital 
usually are those with multiple comorbidities, which may increase their 
original risk for complications. Second, as teaching hospitals usually cover 
wider geographical region, their patient-volume would be bigger than those 
of community non-teaching hospitals. Third, ongoing residency program in 
teaching hospitals usually are more busy and packed with residents, who 
may have higher morbidity rate in outcome of surgical procedures (88).  
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Lastly, in our study patients considered to be at higher risk of reoperation for 
mesh-related surgery did not in fact demonstrate a higher risk. Prior pelvic 
radiotherapy, history of urethral injury or diverticulum, and prior urinary 
fistula are all theoretical predisposing factors for later complications after 
synthetic sling placement because they affect tissue healing and reaction to 
foreign body, although this is based primarily on experts’ opinion. Our 
results can be explained by the small number of patients with those 
predisposed risk factors, which makes it even harder for future study and 
better evaluation. Such results won’t change urologists or gynecologists’ 
daily practice of avoiding synthetic sling placement in this subset of patients, 
but it may encourage them to apply the concept of sling placement in highly 
selected patients when they have such presumed risk factors. 
  
 
5.3 Strength and Limitations 
 
Our study has evaluated a large number of patients who underwent SUI 
surgery for the risk of reoperation for mesh-related complication. It has a 
long follow-up period to document such complication-related operations.  
 
We analyzed a data for almost 60,000 patients with synthetic sling implants, 
with comprehensive data about their baseline criteria, their attending 
surgeon’ specialty, and their attending surgeon’ experience measured as 
surgical volume. This is a credit to the nature of administrative database in 
Ontario, Canada, which was examined and assessed as we explained in 
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methodology chapter. Moreover, due to the unique health care system in 
Canada, and the accessibility of different people to one-government-based 
medical facilities with different surgeons, from which we got our data, we 
can generalize our findings in a more reassured manner.  
 
Finally in our study, we assessed several the effect of covariates that were 
not evaluated in literature previously, which may help in understanding 
different risk factors for mesh-related complications and improve patients 
counseling for synthetic sling placement. This is important in the current 
view of the multiple FDA notifications and ongoing lawsuits in US and 
Canada.  
 
Our study was limited by the following: first, outcome was measured by 
surgical intervention, so we only documented mesh-related complications 
that were treated via surgical intervention. Thus, we likely underestimated 
complications related to mesh that were treated conservatively. Second, we 
could not identify type or severity of incontinence before primary surgery in 
order to study its possible relationship with reoperation rate and its risk. 
Third, there was no information about different types of surgical kits that 
were used in sling implant, and different surgical techniques like retropubic 
or transobturator placement of the sling could not be identified. So, their 
presumed effect on the incidence rate of reoperation for mesh-related 
complication could not be evaluated. Fourth, detailed reasons for which 
slings were removed or excised were not available in all patient’ data. This 
was due to the nature of coding system for surgical procedures. 
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5.4 Future Research 
 
Our study found no difference between urologists and gynecologists in 
reoperation for complications after synthetic sling placement for SUI, which 
is a common entity that is treated by both specialties. This might be the basis 
for further studies and evaluation of other common surgical practice, which 
can facilitate mutual training program that can accept candidates from both 
specialties with focusing on procedure-based surgical skills rather than their 
unique daily practice. 
 
The effect of certain rare variables on reoperation after synthetic sling 
placement needs more evaluation on. Multicentric assessment for example 
can overcome the rarity of such variables and can provide more 
comprehensive information on them. 
 
Finally, academic and teaching hospitals play an important role in training 
clinicians and equip different medical, regional, and local community 
hospitals with surgeons who should be ready to practice independently. For 
this, we think that further studies of different processes of care in teaching 
hospital is vital at all dimensions, in order not to compromise health care 
provided to population in our pathway of training future providers.    
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Appendix A: List of Abbreviation 
 
 
AIDS               Acquired Immune Deficiency Syndrome 
BMI                 Body Mass Index 
CCI                  Canadian Classification of health Intervention 
CI                     Confident Interval 
CIHI                Canadian Institute for Health Information 
CJD                  Creutzfeldt-Jakob Disease 
DAD                 Discharge Abstract Database 
DM                   Diabetes Mellitus  
FDA                  Food and Drug Administration 
HIV                   Human Immunodeficiency Virus  
HR                     Hazard Ratio 
ICD                    International Classification of Diseases 
ICES                  Institute for Clinical Evaluative Sciences 
ICS                     International Continence Society 
IQR                    Interquartile range 
ISD                     Intrinsic Sphincteric Dysfunction 
IUGA                 International Urogynecological Association 
LUTS                 Lower Urinary Tract Symptoms 
MAUDE            Manufacturer and User Device Experience 
MUS                  Midurethral Sling 
OAB                  Overactive Bladder 
OHIP                 Ontario Health Insurance Plan 
POP                    Pelvic Organ Prolapse 
PVS                    Pubovaginal Sling 
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RMUS               Retropubic Midurethral Sling 
SDM                  Standardized difference of the mean 
SDS                    Same Day Surgery 
SIS                     Small Intestine Submucosa 
SUI                    Stress Urinary Incontinence 
TMUS               Transobturator Midurethral Sling 
TOT                  Transobturator Tape 
TVT                  Tension-free Vaginal Tape 
UDS                  Urodynamic Study 
US                     United States 
UTI                   Urinary Tract Infection 
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Appendix B  
 
CCI Codes Used in Identifying Synthetic (Mesh-Based) SUI Procedures 
in OHIP and CIHI-DAD/SDS Databases (Cohort Patients) 
 
CCI Code Dates 
Active 
Description Number 
of 
patients 
in cohort 
1PL74AFFF April 
2002-
March 
2006 
Fixation, bladder neck combined 
open abdominal and endoscopic 
transvaginal approach using 
tension free vaginal tape [TVT] 
technique 
2913 
1PL74AFXXN April 
2002-
Present 
'Fixation, bladder neck 
combined per orifice (vaginal) 
and open (abdominal) approach 
using synthetic material  
3677 
1PL74AFXXQ April 
2003-
Present 
'Fixation, bladder neck 
combined per orifice (vaginal) 
and open (abdominal) approach 
using combined sources of tissue 
[e.g. graft and synthetic tissue] 
66 
1PL74ALFF April 
2002-
March 
2006 
Fixation, bladder neck combined 
percutaneous and vaginal 
approach using tension free 
vaginal tape [TVT] technique 
11535 
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CCI Code Dates 
Active 
Description Number 
of 
patients 
in cohort 
1PL74ALXXN April 
2006-
Present 
Fixation, bladder neck combined 
per orifice (vaginal) and 
percutaneous approach using 
synthetic material (e.g. TVT 
technique) 
32268 
1PL74CRXXN April 
2009-
Present 
'Fixation, bladder neck per 
orifice (vaginal) approach with 
incision using synthetic tissue  
(e.g. TVT technique) 
7932 
1PL74DAXXN April 
2009-
Present 
'Fixation, bladder neck 
endoscopic (laparoscopic) 
(retropubic) approach using 
synthetic tissue  
549 
1PL74LAXXN April 
2006-
Present 
Fixation, bladder neck open 
(retropubic, perineal) approach 
using synthetic material (sling) 
933 
1PL74LAXXQ April 
2006-
Present 
Fixation, bladder neck open 
(retropubic, perineal) approach 
using combined sources  
14 
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Appendix C 
 
CCI Codes Used to Define Primary Outcome 
CCI Code Dates 
Active 
Description 
1PL54CAXXN April 
2006-
Present 
Management of internal device, bladder neck 
of synthetic urethral sling (tension free 
vaginal tape [TVT]) using per orifice 
[vaginal] approach 
1PL54LAXXN April 
2006-
Present 
Management of internal device, bladder neck 
of synthetic material (urethral sling) (tension 
free vaginal tape [TVT]) using open 
approach 
1PL55CAXXN April 
2006-
Present 
Removal of device, bladder neck of synthetic 
urethral sling [tension free vaginal tape] 
using vaginal approach 
1PL55LAXXN April 
2006-
Present 
Removal of device, bladder neck of synthetic 
urethral sling [tension free vaginal tape] 
using open approach 
1PQ56BA April 
2002-
Present 
Removal of foreign body, urethra using 
endoscopic per orifice (transurethral) 
approach 
1PQ56CA April 
2002-
Present 
Removal of foreign body, urethra using per 
orifice approach 
1PQ56DA April Removal of foreign body, urethra using 
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CCI Code Dates 
Active 
Description 
2002-
Present 
endoscopic (percutaneous) approach 
1PQ56LA April 
2002-
Present 
Removal of foreign body, urethra using open 
approach (abdominal, perineal) 
1PQ56QY April 
2002-
Present 
Removal of foreign body, urethra using open 
transvaginal approach 
1PQ57BAGX April 
2002-
Present 
Extraction, urethra using endoscopic per 
orifice approach (transurethral) and device 
NEC [e.g. forceps, meatome] 
1PQ57LAAM April 
2002-
Present 
Extraction, urethra using open approach and 
basket device 
1PQ57LAGX April 
2002-
Present 
Extraction, urethra using open approach and 
device NEC [e.g. forceps, meatome] 
1PQ59BAAG April 
2002-
Present 
Destruction, urethra endoscopic per orifice 
approach using laser 
1PQ59BAAZ April 
2002-
Present 
Destruction, urethra endoscopic per orifice 
approach using ultrasonic probe 
1PQ72AC April Release, urethra using combined open 
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CCI Code Dates 
Active 
Description 
2002-
Present 
abdominal with vaginal approach 
1PQ72LA April 
2002-
Present 
Release, urethra using open approach 
1PQ72PK April 
2002-
Present 
Release, urethra using open retropubic 
approach 
1PQ72QY April 
2009-
Present 
Release, urethra using open transvaginal 
approach 
1PQ72QYAG April 
2002-
Present 
Release, urethra using open transvaginal 
approach and laser 
1PQ86MB April 
2002-
Present 
Closure of fistula, urethra simple excision 
and closure terminating at skin 
(urethrocutaneous, urethroscrotal, 
urethroperineal) 
1PQ86MD April 
2002-
March 
2009 
Closure of fistula, urethra NEC simple 
excision and closure terminating in genital 
tract [urethrovaginal] 
1PQ86MH** April 
2009-
Closure of fistula, urethra simple excision 
and closure terminating in genital tract 
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CCI Code Dates 
Active 
Description 
Present [urethrovaginal] 
1RS55CAXXN April 
2003-
Present 
Removal of device, vagina of synthetic 
material (e.g. mesh, sling) using per orifice 
approach 
1RS55LAXXN April 
2002-
Present 
Removal of device, vagina of synthetic tissue 
(e.g. mesh) using open approach 
1RS56CA April 
2002-
Present 
Removal of foreign body, vagina using per 
orifice [vaginal] approach (for simple 
extraction) 
1RS56CR April 
2002-
Present 
Removal of foreign body, vagina using per 
orifice [vaginal] approach and incisional 
technique 
1RS56DA April 
2006-
Present 
Removal of foreign body, vagina using 
endoscopic (laparoscopic) approach 
1RS56LA April 
2006-
Present 
Removal of foreign body, vagina using open 
(abdominal) approach 
1RS86LAXXE April 
2002-
March 
2006 
Closure of fistula, vagina NEC terminating at 
skin, using open (perineal) approach and 
local flap repair 
1RS86MB April Closure of fistula, vagina for fistula 
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CCI Code Dates 
Active 
Description 
2006-
Present 
terminating at skin (vaginal, perineal) and 
simple apposition (suturing) for closure 
1SZ55LAXXN April 
2002-
Present 
Removal of device, soft tissue of the chest 
and abdomen of mesh using open approach 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
Appendix D 
 
 CCI Codes Used to Identify Study Covariates 
Covariate Source Codes 
Obesity OHIP 
CIHI-
DAD/SDS 
(ICD 10) 
CIHI-
DAD/SDS 
(ICD 9) 
E676, E010 
E66x Obesity 
 
278.x Obesity 
Pelvic 
organ 
prolapse 
repair 
(with or 
without 
mesh) 
CIHI-
DAD/SDS 
(CCP*) 
82.40 Anterior & Posterior repair 
82.41 Anterior repair 
82.42 Posterior repair 
82.43 Anterior & Posterior Repair 
81.30 Repair of uterine support 
81.31 Interposition 
81.32 Other uterine suspension 
81.33 Vaginal repair chronic uterine inversion 
81.39 Other repair of uterine support 
Pelvic 
organ 
prolapse 
repair 
(with 
mesh) 
CIHI-
DAD/SDS 
(CCI) 
1RS80CRXXN Synthetic repair vagina 
(Vaginal approach) 
1RS80CAXXN Synthetic repair vagina 
1RS80LAXXN Synthetic repair vagina, 
(abdominal approach) 
1RS80DAXXN Synthetic repair vagina (MIS 
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Covariate Source Codes 
approach) 
1RS80CRXXQ Repair vagina combined 
source 
1RS80CAXXQ Repair vagina combined 
source 
1RS80LAXXQ Repair vagina retropubic 
combined tissue source 
1RS74CRXXN Repair vagina with synthetics 
1RS74LAXXN Abdominal repair vagina with 
synthetics 
1RS74DAXXN Repair vagina synthetics Lap 
1RS74CAXXN Fixation vaginal approach 
with mesh 
Any 
prolapse 
repair 
OHIP S716 S717 S718 S719 S723 S720 S721 S722 
S812 S760 S813 S761 S758 S759 
 CIHI-
DAD/SDS 
(CCI) 
1RS74 Fixation vagina 
1RS80 Repair vagina 
 CIHI-
DAD/SDS 
(CCP) 
82.40 Anterior & Posterior repair 
82.41 Anterior repair 
82.42 Posterior repair 
82.43 Anterior & Posterior Repair 
81.30 Repair of uterine support 
81.31 Interposition 
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Covariate Source Codes 
81.32 Other uterine suspension 
81.33 Vaginal repair chronic uterine inversion 
81.39 Other repair of uterine support 
Prior 
possible 
mesh based 
SUI 
procedure 
CIHI-
DAD/SDS 
(CCP) 
71.40 Suprapubic sling operation 
71.60 Periurethral suspension and 
compression 
Urologic 
visit 
OHIP A355, C355, W355, A356, C356, W356, 
A353, C353, C354, A354 
Gynecologi
c visit 
OHIP A205 A206 A203 A204 C205 C206 C203 
C204 W305 W306 
Hysterecto
my 
OHIP S757 S816 S763 S762 S710 S758 S759 
 CIHI-
DAD/SDS 
(CCI) 
5CA89CK Vaginal Hysterectomy with 
pregnancy 
5CA89GB MIS hysterectomy with pregnancy 
5CA89WJ Open hysterectomy with pregnancy 
5CA89WK Open hysterectomy with 
pregnancy 
5MD60KE Cesarean section hysterectomy 
5MD60RC Cesarean section hysterectomy 
with forceps 
5MD60RD Cesarean section hysterectomy 
with vacuum 
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Covariate Source Codes 
1RM89 Total hysterectomy 
1RM91 Radical hysterectomy 
 CIHI-
DAD/SDS 
(CCP) 
86.42 Hysterectomy with pregnancy 
80.30 Total abdominal hysterectomy 
80.40 Vaginal hysterectomy 
80.50 Radical hysterectomy 
80.60 Radical vaginal hysterectomy 
High risk 
mesh 
patient: 
Prior 
fistula 
CIHI-
DAD/SDS 
(CCI) 
1PQ86MH Urethrovaginal fistula excision and 
closure 
1PQ86MD Urethrovaginal fistula excision and 
closure 
1PQ86MB Urethral fistula excision and 
closure 
1RS86MB Vaginal fistula closure 
1RS86CAXXE Vaginal fistula closure 
1RS86LAXXE Vaginal fistula closure 
 OHIP S709A, S523A, S524A 
 CIHI-
DAD/SDS 
(CCP) 
70.33 Closure of fistula to urethra 
 
High risk 
mesh 
patient: 
Prior 
urethral 
CIHI-
DAD/SDS 
(CCI) 
1PQ87QY Partial excision urethra 
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Covariate Source Codes 
diverticulu
m 
 CIHI-
DAD/SDS 
(CCP) 
70.20 Excision or destruction of urethral 
lesion 
82.52 Vaginal reconstruction diverticulum 
 OHIP S541 
High risk 
mesh 
patient: 
Prior 
radiation 
therapy 
CIHI-
DAD/SDS 
(CCI) 
1PQ27JA Radiation urethra, external beam 
1PM27JA Radiation bladder, external beam 
1RM26 Radiation uterus, brachytherapy 
1RM27JA Radiation uterus, external beam 
1RZ27JA Radiation female genital tract 
1RN26 Radiation cervix, brachytherapy 
1RN27 Radiation cervix, external beam 
1NQ27JA Radiation rectum, external beam 
1NT26CA/HA/LA Radiation anus, 
brachytherapy 
1NT27JA Radiation anus, external beam 
1RB27JA Radiation ovary, external beam 
1RS26 Radiation vagina, brachytherapy 
1RS27JA Radiation vagina, external beam 
High risk 
mesh 
patient: 
Prior 
urethral 
CIHI-
DAD/SDS 
ICD10 
S37.3 Injury of urethra 
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Covariate Source Codes 
injury 
 CIHI-
DAD/SDS 
ICD9 
867.0 Injury bladder or urethra 
867.1 Open injury bladder or urethra 
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